Navigation Links
PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations

SOUTH PLAINFIELD, N.J., June 1 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Clare Kennedy has been appointed as Vice President of Commercial Operations. In this role, she will report to Theresa Natalicchio, Senior Vice President, Commercial, and will be responsible for PTC's patient services and distribution functions focusing on product access and reimbursement.

(Logo: )

"We are delighted to welcome Clare to our management team," said Ms. Natalicchio. "Clare's extensive expertise in national healthcare customer management, contracting and distribution will be a great asset as we expand our commercial organization and prepare for the launch of ataluren."

"I am excited to join PTC," commented Ms. Kennedy. "The company has shown an exemplary advancement of its diverse pipeline and I look forward to being part of the commercial organization with a goal to bring PTC's innovative therapies to patients."

Prior to joining PTC, Ms. Kennedy spent 16 years at Pfizer, most recently as Vice President of Account Planning, overseeing national account management, customer contracting and product access in the U.S. for the company's $21 billion portfolio. Ms. Kennedy was responsible for U.S. sales in various areas including commercial health plans, pharmacy benefit management companies, long-term care, employers, and federally-funded programs. Prior to Pfizer, Ms. Kennedy started several small businesses involved in preventive health care and clinical research. She received an A.A.S. in Nursing from Long Island College Hospital, a B.S. in Health Science from St. Francis College and a M.S. in Health Management from the American University School of Business and College of Arts and Sciences. Ms. Kennedy is also a Registered Nurse.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control of RNA processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases. PTC has extensive knowledge of post-transcriptional control processes and has developed proprietary technologies that it applies in its drug discovery activities internally and in collaborations with leading biopharmaceutical companies such as Genzyme, Pfizer, Celgene, Gilead and Schering-Plough. For more information, visit the company's Web site at

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
2. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
3. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
7. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
8. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
9. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
10. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
11. Orexigen(R) Therapeutics to Present at Upcoming Meetings
Post Your Comments:
(Date:10/9/2017)... , ... October 09, 2017 , ... At its national ... Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been ... a member of the winning team for the 2015 Breakthrough Prize in Fundamental physics ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, ... Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... within the healthcare and technology sector at their fourth annual Conference where founders, ... 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage digital health ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:3/30/2017)... -- On April 6-7, 2017, will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):